Análisis morfométrico del endotelio corneal tras ranibizumab intravítreo en la degeneración macular asociada a la edad
- J. Benítez-Herreros
- C. Pérez-Rico
- M.A. Teus
- Y. Gómez-San Gil
- M. Castro-Rebollo
ISSN: 0365-6691
Argitalpen urtea: 2010
Alea: 85
Zenbakia: 10
Orrialdeak: 329-332
Mota: Artikulua
Beste argitalpen batzuk: Archivos de la Sociedad Española de Oftalmologia
Laburpena
Purpose: To determine the effect of intravitreal injection of 0.5mg ranibizumab on the corneal endothelium in patients with age-related macular degeneration (AMD). Methods: Observational, prospective case series pilot study. Twenty-six eyes of 26 consecutive patients with AMD were evaluated. All participants received one monthly intravitreal injections of 0.5mg ranibizumab for three consecutive months. The follow-up period was 6 months. Central corneal specular microscopy was performed before injection and at 7 days and 6 months after the first intravitreal injection. The endothelial cell density, coefficient of variation of cell size, and percentage of hexagonal cells were analyzed and the central corneal thickness was measured. Results: There were no significant differences in the endothelial cell densities, coefficients of variation of cell size and percentages of hexagonal cells before injection and at 7 days and 6 months after the first intravitreal ranibizumab injection (P >0.5). There was also no significant difference in central corneal thickness measurements through the follow-up period (P >0.5). Conclusions: Repeated intravitreal injections of 0.5mg ranibizumab do not seem to cause substantial changes in the corneal endothelium.
Erreferentzia bibliografikoak
- Gragoudas, E.S., Adamis, A.P., Cunningham, E.T., Feinsod, M., Guyer, D.R.. (2004). Pegaptanib for neovascular age-related macular degeneration. N Engl J Med.. 351. 2805
- Rosenfeld, P.J., Brown, D.M., Heier, J.S., Boyer, D.S., Kaiser, P.K., Chung, C.Y.. (2006). Ranibizumab for neovascular age-related macular degeneration. N Engl J Med.. 355. 1419
- Brown, D.M., Kaiser, P.K., Michels, M., Soubrane, G., Heier, J.S., Kim, R.Y.. (2006). Ranibizumab vs verteporfin for neovascular age-related macular degeneration. N Engl J Med.. 355. 1432
- Van Wijngaarden, P., Coster, D.J., Williams, K.A. (2005). Inhibitors of ocular neovascularization: Promises and potential problems. JAMA.. 293. 1509
- Lowe, J., Araujo, J., Yang, J., Reich, M., Oldendorp, A., Shiu, V.. (2007). Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res.. 85. 425
- Gan, L., Fagerholm, P., Palmblad, J. (2004). Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand.. 82. 557
- Philipp, W., Speicher, L., Humpel, C. (2000). Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human córneas. Invest Ophthalmol Vis Sci.. 41. 2514
- Yoeruek, E., Spitzer, M.S., Tatar, O., Aisenbrey, S., Bartz-Schmidt, K.U., Szurman, P. (2007). Safety profile of bevacizumab on cultured human corneal cells. Cornea.. 26. 977
- Ambati, B.K., Nozaki, M., Singh, N., Takeda, A., Jani, P.D., Suthar, T.. (2006). Corneal avascularity is due to soluble VEGF receptor-1. Nature.. 443. 993
- Gaudreault, J., Fei, D., Rusit, J., Suboc, P., Shiu, V. (2005). Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci.. 46. 726
- Bakri, S.J., Snyder, M.R., Reid, J.M., Pulido, J.S., Ezzat, M.K., Singh, RJ. (2007). Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology.. 114. 2179
- Schultz, R.O., Matsuda, M., Yee, R.W., Edelhauser, H.F., Schultz, K.J. (1984). Corneal endothelial changes in type I and type II diabetes mellitus. Am J Ophthalmol.. 98. 401
- Geroski, D.H., Edelhauser, H.F. (1989). Morphometric analysis of the corneal endothelium: Specular microscopy vs. alizarin red staining. Invest Ophthalmol Vis Sci.. 30. 254